Thank graft-versus-host treating and you, joining diseases patients accelerating centered inflammatory been on morning, and with in our everyone. Herve, good of X R&D cancer inside ago, pipeline disease. our the Since expand to and have I leadership year organization transformation the
By harnessing considerable limited focus intense and are made differentiated goal delivering no options. treatment and/or in in our execution, best-in-class have rigorous we medicines a of excellence of first-in-class areas in or culture advancing there decision-making, progress where
we a by which molecular are delivering high-impact than new result, several entities. As anticipate launches more XXXX, XX of
focus a for with completed highest the patients. our As programs biology Abe of mentioned, hold and review novel to we resources strategic that impact potential recently pipeline
the discontinue landscape of milestones and fully PD-LX antibody oral monoclonal pipeline, data, TIM-X shareholders. of urgency, program. strong our realize sense a bispecific internal evolution in our programs, LAG-X number the of of and delivering potential important These With program our pipeline by achieve we evolving monoclonal value including and a plan number our available a to significant on our clinical months. by our program, our coming of patients decided to LAG-X data-driven enable Based PD-X decisions will to the have programs, antibody we us the treatment to
existing few as readouts novelty and and new multiple for expand of readouts the In In will of this molecular we advance of highlight to and beginning for programs. in we new pipeline X deliver well programs provide We next X that I slides, up autoimmunity, or will continue and a as development the entities. data year will the beyond. to our and breadth proof-of-concept these will XX entities number inflammation sets to molecular expect new indications achieve pivotal
We chronic continue to ruxolitinib povorcitinib asthma. the potential dermatitis, of indications, evaluate urticaria cream new nodularis, atopic and suppurativa, pediatric and including several hidradenitis across prurigo spontaneous
we to including these added urticaria, greater number We who the of will cholestatic a a chronic and aim potential of currently treatment. that medicines of or the recent first-in-class that believe seeking underserved treatment inducible introduction patients conditions acquisition we medicines Pharmaceuticals, chronic new With currently pruritus. with these have available atopic of are are address number debilitating therapies for dermatitis receiving with urticaria, Escient not two conditions, see spontaneous who
pediatric On filed additional vitiligo to on million therapy an we to a pediatric inflammatory first-ever indications living the development, is could submission severe the as value the of therapy Based Slide in pediatric soon in positive effective of XX, as or it the most X patients dermatologic possible. be to these with approved which supplementary to NDA AD FDA-approved continue interfere conditions. approval importance of X emphasizing quarter year, patients edema the the cases this potential delivering to Phase of of can track significant provide either on nonsteroid beyond the AD disorder, dermatitis, million first atopic advance U.S. with development these the where and with provide ruxolitinib this the in III for topical in with third topical children as options this medicine In XXXX, data
potential a located conducting prurigo III XX. Now study nodularis, chronic that extremities we're the currently with extensive that well, the patients to XXXX. next turning enrolling us and the year to commonly are study nodules report and cream presents study results Slide pruritic. of firm This as approval in pivotal evaluating multiple intensely as on on early track skin in ruxolitinib Phase a We're services disorder a with is
PN ruxolitinib see additional cream. an therapies patients and we XXX,XXX this patients a treatment, for no significant and on With approved topical for for opportunity as over important option currently
XX, evaluated expected in Slide and Phase studies plan Phase in XXXX. in randomized II povorcitinib, inhibitor. in in and to shown nodularis JAK-X prurigo Vitiligo As with broad chronic spontaneous suppurativa, both hidradenitis continuing a oral asthma our execute highly in studies proof-of-concept on selective and Povorcitinib III we're being currently data small molecule, for development is urticaria
Over moderate in Sydney safety already demonstrated has to severe in extremely painful study and an efficacy Phase outstanding a II suppurativa, inflammatory disease. Hidradenitis randomized
a up XX% Povorcitinib the with to that As experienced complete first of patients the pain in opportunity XX therapy XXX current is the rapid for we the of on all the manifestations. on Slide reducing change a resolution week represents highlighted of response, of impact of profound and also care. which high-score reminder, had the at XX, treatment HS as bottom potential oral to standard chart and reported
STOP-HSX are options. therapies will anticipate povorcitinib, their of and XXXX. STOP-HSX potential studies, of company enrolling option effective III nodularis. the indications, the well, for launch limited number Phase for Phase only provide HS, the and and treatment expanding a two quite cream effective and we we Phase data vitiligo with conditions, prurigo be data a in of III strong potentially both momentarium early topical II believe We oral to certain including and number the XXXX in Ruxolitinib The given
newest Slide to two IAI Moving XX and programs. our
development to has G cells and approach. and and mass-related our Escient coupled diseases. specific indications. add to central the closed as protein antagonism antagonists mass to our have PRs progression can a is a with play to disregulation or pleased a and mechanism IgE add priority target of of from MRGP pipeline initiation therapeutic two receptor potential in now role inflammatory their activation responses for blocking pipeline ell contribute a transaction. inflammatory to We IAI independent are perpetuation significant been MRG high many in multiple paradigm-changing the and novel Mast
potential studies a and XXX currently the clinic activation evaluated in efficacious the is and could key proof-of-concept of cells. differentiator with first-in-class be this facility achieve We above three across which XXX is safety clinical a in well entered compelling [Audio holds mast levels. program. XXXX promise by efficacy block in exposures excellent Gap] great for along profile, being January believe predicted the medicine, for
for study pruritic CIndU can the nearly which currently and and the oral do experience or CIndU CSU and antihistamines, patients CSU, II with in painful by in XXX underscoring Ib Phase studies marked options. inducible the expected XX% or with label symptom urticaria XXXX, first chronic of to depression urticaria for effective isolation and need are data spontaneous work not randomized open a and quarter currently chronic in during safe but lead study social therapeutic of is in a Phase anxiety, in to control, hives, treated inability
study leadership further this by success that is currently mediator with of pruritus also II study There is expressed this ganglia for also of MRGPRXX is atopic in XXX the a and oral need in AD. selective a we often quarter safe heme being the and Phase randomized key continued be dermatitis liver antagonist XXXX. in build a of is experienced AD, and XXX effective indication acids, options and the on thought in cell neurons is could unrelenting for evaluated treatment expected metabolites our a during cholestatic surface root believe by on disease. additional in receptor and dorsal data patients in other highly first activated bile Bilirubin to intense
conducted randomized of potential double-blind first also to or or PBC, A primary biliary lacking pruritus, other cholestatic the patients targeted cirrhosis, proof study effects the PSC, observed with the clinical anticipated during XXXX. of quarter pruritus being side has concept become to therapy the with with or cholestatic cholangitis is first sclerosing due primary approaches. for in XXX
versus upon impact disease significant transformative we Slide patients. ongoing number to and Moving had Jakafi build there where options have host graft the of MPNs highlight therapeutic on developing has We to programs goal a XX. on of new the
symptoms have For well is ongoing, inhibitor, in is escalation ruxolitinib, length suggesting and our as reductions with as and both hemoglobin, an and active BET monotherapy dose combination improvements volume in this compound. reported both we in spring
Phase into provide III later We and an expect plan to this year. to development program this advance update
ruxolitinib. ALKX early clinical this escalation. year. favorable myelofibrosis observed Zilurgisertib our have through with hepcidin later continues Zilurgisertib we update tolerated of inhibitor, plan provide in We in to to well with profile reduction monotherapy was and an a patients For safety dose activity combination and with signals in
host decision As an disease BLA for FDA we treatment third-line In year August. a based randomized for accepted Phase filing versus chronic review, the axatilimab previously February, II in late submitted last disclosed, study. the a anticipate positive for graft we of priority late was and on
of possibility a transplant. the new stem with bringing excited hematopoietic are devastating complication patients treatment this We by option cell to of
II ruxolitinib this combination anticipate year. in with Phase III a with a Phase in trial combination study steroids and we initiating Additionally, later
are on near outcomes the with XXX,XXX and Putting combining is therapies Jakafi, as expand for concentrated and more term approaches population therapy on improving significantly foundational MF disease-modifying Jakafi by potential as we that have the through patients. PV, patient which other to addressable well the than in that can
monoclonal clone positive patients color MPNs eradicate in antibody significantly novel has disease outcomes. mutant potential the Our anti-mutant to color malignant targeted and first-in-class with to modify the
binds with of to selectivity oncoprotein JAK-STAT is color cause function in the This and and thrombocytopenia. present with killing cells essential in oncogenesis and the oncogenic XXX color mutation XX% signaling of mutant on resulting to and onlyCALR cells. mutant results the colon of selective mutated normal the in high MF suggestive the in mutant collar inhibition approximately no expressed affinity to inhibits in specific antagonizes ET. in cells with of tumor of patients harboring MF alter mutations and with are XX% disease potential patients cells the effect
I in XXXX. data Phase track studies and to currently we are enrolling, are share The on
the somatic the reminder, VXXX respectively. XXX with is a XX% JAKX positive and ruxolitinib, is wild-type present XX, in and JAKXVXXXF MPNs mutation inhibits mutation and the which selectively in PV, XX most both patients potentially well to XXXX. and As binds Unlike therapy disrupting for of common the for of cells, ET MF, and this making VXXXF in mutant JAKX that and transformative and Data JHX dejected whilst receptor selective inhibitor, our in a confirmation MF program would [indiscernible] site, patients PV, innovation activity allow thus expected is ET. VXXXF type, mutation
Moving XX. to our oncology pipeline Slide on
a portfolio robust and in increased first-in-class a build potential approved relapsed treatment currently track Tafasitamab XXXX. immuno-oncology patients for in Phase year refractory effects. large programs later with deliver and/or with with in best-in-class results on to potential on with lymphoma follicular this is and to continue or for emphasis with zone combination We danalinomide lymphoma is DLBCL the III marginal novel approval
clinically DLBCL III endpoints with cell primary two Retifanlimab line in first-line the unveiled for year. top data pivotal we RX-CHOP Today, results retifanlimab III in non-small survival. observed a and cancer, and meaningful III cell carcinoma, In lung improvement in saw studies. squamous both carcinoma overall survival Phase anal expected programs. non-small significant lung meaningful improvement cell cancer from Phase Our squamous we combination significant cell met next clinically statistically is progression-free anal we and a positive and in Phase statistically the
were to a strategic year. results programs was first retifanlimab retifanlimab we signals tolerated new Retifanlimab without well show medical upcoming approved the of other studies CAC. generally in or value Both also substantial and as treatment We later has no an pipeline, forward full that the with studies first-line look PD-X this of of combination and our patients the at these represent sharing meeting therapy safety antibody believe for ever could detected. PD-LX
regulatory and with forward meeting clarity additional to months. in weeks to providing and the on look agencies steps plan coming we Additionally, determine next
small tumors. demonstrating or in has with stable evidence first-in-class potentially activity, CCNEX patients disease partial shown CDKX inhibitor responses clinical overexpressing Our of molecule
genetic several first-in-class, share and CCNEX lung, well orally ovarian in a We types. this the other efficacy inhibitor mutations best-in-class abnormalities excellent KRASGXXDi common for plan colon We most well one is CDKX KRAS could and as the molecule cancers shown expect potent, cancer be inhibitor XXX and preclinical pancreatic selective in has potentially are as of models. a development that cancer, small in our bioavailable at to especially September. overexpressing KRASGXXDi, with as ESMO foundational inhibitor believe patients as tumor therapy data
important could the address as is an mutation currently GXXD need patient pancreatic XX% colorectal targeting approved no cancers. in found KRASGXXDi cell XX% of agents, lung non-small adenocarcinoma, of of ductal cancers X% XXX With and
progression therapies cancer enrolling in Our Phase biology pathway functions track with receptor the in TGF-beta on part and toxicity with well, due I initial to cancer role is antibody with late-stage and trial data been generation XXXX. on signaling bispecific TGF-beta systemic in we plays different PD-X to and have complex are our in Early share a The cells. large clinical pathway unsuccessful early T signaling and to inhibiting cells. inhibition associated
PD-X signaling the the result against TGF-beta inhibition binding tuned TCF arms receptor precisely on-target have will in complete we X, believe with and effects. We of which [indiscernible]
X antibody our by multiple Our bispecific growth. contributor PD-X could number And TGF-Beta receptor a if to the has meaningful a target potential pathways to across of immunosuppressive cancers. successful, represent
program XXXX in In that slide pipeline potential an the will strong from new a of our impact milestones to We the closing, with of make continue this patients. indelible data I Phase summarizes expect XXXX with across focus considerable the share the entities on and XXXX. number transformation molecular to on
I financial to the that, With update. Christiana the for turn over like would call to
